Patents by Inventor Julia SCHNABEL

Julia SCHNABEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-GLYCO-CMET ANTIBODIES AND THEIR USES
    Publication number: 20250136701
    Abstract: The present disclosure relates to anti-glyco-cMET antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of cMET and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Application
    Filed: September 2, 2022
    Publication date: May 1, 2025
    Applicant: GO Therapeutics, Inc.
    Inventors: Hans WANDALL, Julia SCHNABEL, Edwin TAN, Richard Johnson MORSE, Jr., Aaron GROEN
  • ANTI-GLYCO-MUC4 ANTIBODIES AND THEIR USES
    Publication number: 20250101126
    Abstract: The present disclosure relates to anti-glyco-MUC4 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC4 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Application
    Filed: August 4, 2022
    Publication date: March 27, 2025
    Applicant: GO Therapeutics, Inc.
    Inventors: Hans H. WANDALL, Julia SCHNABEL, Edwin TAN, Richard J. MORSE, JR., Aaron GROEN
  • ANTI-GLYCO-LAMP1 ANTIBODIES AND THEIR USES
    Publication number: 20250066498
    Abstract: The present disclosure relates to anti-glyco-LAMP1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of LAMP1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Application
    Filed: September 2, 2022
    Publication date: February 27, 2025
    Applicant: GO Therapeutics, Inc.
    Inventors: Hans WANDALL, Julia SCHNABEL, Edwin TAN, Richard Johnson MORSE, Jr., Aaron GROEN
  • ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES
    Publication number: 20230126689
    Abstract: The present disclosure relates to anti-glyco-CD44 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of CD44 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Application
    Filed: March 5, 2021
    Publication date: April 27, 2023
    Applicant: GO Therapeutics, Inc.
    Inventors: Julia SCHNABEL, Edwin TAN, Hans H. WANDALL, Aaron GROEN